A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 10(5.3) PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 10(3) PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.
Bukreyev
Alexander
A
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. abukreyev@niaid.nih.gov
Yang
Lijuan
L
Zaki
Sherif R
SR
Shieh
Wun-Ju
WJ
Rollin
Pierre E
PE
Murphy
Brian R
BR
Collins
Peter L
PL
Sanchez
Anthony
A
D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000097:blood; D002522:Chlorocebus aethiops; D003588:Cytopathogenic Effect, Viral; D004195:Disease Models, Animal; D046129:Ebola Vaccines / Q000008:administration & dosage / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control*; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D009500:Neutralization Tests; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology; D010224:Parainfluenza Virus 3, Human / Q000235:genetics; D013154:Spleen / Q000473:pathology; D016019:Survival Analysis; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014766:Viremia
D000914:Antibodies, Viral; D000956:Antigens, Viral; D046129:Ebola Vaccines; D009698:Nucleoproteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C113189:envelope glycoprotein, Ebola virus